This year (2014) is the twentieth anniversary of the formation of the Australian and New Zealand Intensive Care Society's Clinical Trials Group (CTG) 1 . In this short time, the CTG has acquired an impressive curriculum vitae, gained an enviable international reputation, attracted $60 million in research grants and produced nearly 100 publications in pre-eminent peer-reviewed journals.
This phenomenal achievement is due to a modest, but dedicated, band of doctors, nurses and administrative staff responsible for governance, grant preparation, ethics submission, education, project oversight, data monitoring, analysis, writing, presentation and publication. Add to these the thousands of bedside and research nurses, without whom there would be no data to analyse, present or publish. They all deserve our gratitude.
Critics of the CTG may draw attention to one important missing element, conspicuous by its absence. The elephant in the room is the 'positive' trial. That is, research that has led to the introduction of a novel therapy that improves outcome. To date no CTG investigation has resulted in an unequivocal 'positive' result. CTG research has only proven that trial therapies are no better than standard care and may even be harmful. It has proscribed rather than prescribed. Homeostasis and current practice have repeatedly won the day.
The CTG is not alone in producing high-quality 'negative' trials. There are numerous interventions that were once considered routine care-so much so that claims of negligence attended their absence-that have since been exposed through robust research to be, at best, a distraction or, at worst, more dangerous than the disease they purported to treat (Table 1) .
Does this surfeit of 'negative' research indicate that intensive care is unnecessary? Available evidence would suggest otherwise. In 1994, the same year that the CTG was formed, a list of 500 (medical and nonmedical) life-saving interventions in the USA was published 2 . The authors declared that intensive care treatment was more cost-effective than many less expensive and more widely accepted interventions such as smoke detectors in homes and airbags in vehicles! Do 'negative' research results indicate that intensive care has reached the peak of its efficiency and efficacy? Has standard care reached its ceiling Table 1 Examples of routine therapies no longer in use Frusemide in oliguric renal failure 31 High dose steroids in sepsis or acute respiratory distress syndrome 32 Prophylactic lignocaine in acute coronary syndrome 33 Transfusion for normovolaemic anaemia 9 Bolus fluid resuscitation (paediatric malaria 34 , penetrating trauma 35 ) Routine pulmonary artery catheterisation 36 Bicarbonate for metabolic acidosis 13 Balloon pump for cardiogenic shock 14 with no room for improvement? Local evidence would suggest otherwise. Intensive care survival in Australia and New Zealand has continued to improve over the past 20 years 2,3 despite the absence of any groundbreaking CTG research or novel therapies.
Point of View
What do clinicians working at the coalface make of all this? Has the CTG been a distraction? Has the CTG been asking the wrong questions? Has the CTG dog been barking up the wrong research tree? Has the CTG afforded positive contribution to patient care? Has any CTG product truly enhanced patient outcome and survival?
For several reasons, the answer must be resoundingly in the affirmative. The CTG has illustrated the fatal attraction of surrogate endpoints, the hazards of single-centre trials, cautioned against ineffective therapy and, in the process, saved lives and money.
It would be reasonable, for example, to argue that the CTG has induced a massive 'Hawthorne' effect 5, 6 . It has provided the medium for much debate and activity focused on the quality of patient care.
It is therefore, difficult to ignore the hypothesis that the CTG is responsible for the evolution and advancement in standard care and unrelenting improvement in outcomes 3, 4 . If there was no CTG would the high calibre of Australian and New Zealand intensive care units be the same? Would the gains be as great? Attractive as this hypothesis may be, it remains unproven.
Are there other benefits from negative trials? Has the CTG accomplished more than prescribing 'what not to do'? Has the publication of negative trial results translated into practice improvement? There is one thread that emerges quietly from the fog of data analysis and interpretation, yet scarcely receives attention.
The implicit conclusion, based on CTG (and much other) research, is that we should focus on the fundamental elements of good patient care, and not succumb to distraction by interventions of unproven benefit. We should not allow time-consuming, secondary and unhelpful interventions to distract us from the primary goal(s).
There is a time for everything. There is a time for timely and active clinical intervention. There is also a time for inactivity-masterly inactivity and careful repeated observation (MICRO) therapy. At the very least, the negative research trial discourages us from exposing patients to unnecessary therapy 7 . Such therapy may be harmless, but it may also be the enemy of a better outcome. Superfluous therapy distracts our attention and exposes patients to avoidable adverse events.
MICRO therapy is a simple concept but difficult in practice, particularly intensive care practice. We have been trained to develop a time-critical mindset: don't just stand there, do something and do it now, before it's too late! We shun indolence and tardiness. We are frequently tempted to do anything for the sake of doing something.
Through unnecessary interventions we risk becoming distracted, causing avoidable harm and hindering recovery. Distraction is a singular risk in the intensive care unit. Our armamentarium provides us with the ability to measure a myriad of physiological systems, order a plethora of laboratory investigations and the means to incessantly fine-tune the numbers. It is all too easy to give in to the temptation to do something, anything, rather than nothing.
It is not that abnormal physiology or our inactivity is therapeutic; rather, the unwarranted intervention becomes the wrong intervention. Oliguria, anaemia, hypovolaemia, hypokalaemia, acidosis and cardiogenic shock are indicators of serious illness and associated with adverse outcomes. Unfortunately, the infusion of dopamine 8 , blood 9 , colloids 10,11 , potassium 12 , bicarbonate 13 or cardiac assist devices 14 only correct the abnormal sign and do not cure the disease, nor improve the outcome. They become interventions that are no better or even worse than the disease they seek to cure.
All interventions carry risks. Investigations may mislead. Our obsession with fine-tuning may lead to numerology. Succumbing to distraction may rob time from the essentials of good patient care.
Masterly inactivity is not a new concept. It was first coined in 1828 by American Congressman John Randolph: "We ought to observe that practice which is the hardest of all-especially for young physicians-to observe a wise and masterly inactivity". It is echoed by the phrase: "Primum non nocere" 15 (First, do no harm). More recently, Groopman 16 stated "there exist situations [in medicine] in which inaction may be the wisest course of action". Chesterton asserted that the best outcome often "depends on not doing something which you could at any moment do and which, very often, it was not obvious why you should not" 17 . The 13th Law of The House of God decreed that, at times, "the delivery of good medical care is to do as much nothing as possible" 18 .
There is a growing list of intensive care therapies that were once considered routine until they were subject to (multi-centre, prospective, randomised, placebocontrol) investigation by the CTG and recognised to be either harmful 11, 19, 20 or unhelpful 8, 10, [21] [22] [23] [24] (Table 2) .
Translation of our research into clinical practice also provides intriguing insights. The first CTG trial 8 disproving outcome benefit from renaldose (2 to 5 µg/kg/minute) dopamine led a senior intensivist to exclaim: "But it's like underwear; it's going to be very difficult to stop putting it on every morning!". Dopamine is now an almost forgotten drug. Surprise and disbelief also accompanied the Medical Emergency Response Intervention Trial (MERIT) study 25 , but did not prevent the widespread introduction of medical emergency teams into hospital practice and the characterisation of its methodological flaws 26, 27 . Disappointment, notably amongst neurosurgeons, followed the publication of the decompressive craniectomy (DECRA) trial showing that control of refractory intracranial hypertension by decompressive craniectomy translated into worse outcomes 21 .
Conversely, there was elation, particularly from nursing staff, following the Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial 19 suggesting that labour-intensive tight glycaemic control (4.4 to 6.1 mmol/l) may increase mortality. Honourable satisfaction attended the publication of the intravenous fluid therapy (Saline versus Albumin Fluid Evaluation (SAFE) 10 and Crystalloid Hydroxy-Ethyl Starch Trial (CHEST) 11 ) trials. Albumin was no longer a fatal fluid as the Cochrane Group had suggested 28 and Voluven ® was no longer the wonder synthetic colloid 29 .
CTG trial results have alerted us to the absence of benefit 8, 21, 23 or increased harm 19, 20 that may attend single-centre studies 30 and surrogate endpoints such as polyuria, glycaemic control, metabolic demand and intracranial pressure. The CTG has played an important role in improving patient care, not least because it has cleared some of the accumulated detritus from the intensive care landscape, making it easier to see the road ahead and the temptation of scenic detours.
It may be some time before the CTG produces a study with a positive innovation. Even then, it may be that the single most positive intervention of the CTG has been the CTG itself.
